Endometriosis - Pipeline Review - H1 2015





Global Markets Direct’s, ‘Endometriosis - Pipeline Review, H1 2015’, provides an overview of the Endometriosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endometriosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometriosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
Introduction 10
Global Markets Direct Report Coverage 10
Endometriosis Overview 11
Therapeutics Development 12
Pipeline Products for Endometriosis - Overview 12
Pipeline Products for Endometriosis - Comparative Analysis 13
Endometriosis - Therapeutics under Development by Companies 14
Endometriosis - Therapeutics under Investigation by Universities/Institutes 17
Endometriosis - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Endometriosis - Products under Development by Companies 22
Endometriosis - Products under Investigation by Universities/Institutes 24
Endometriosis - Companies Involved in Therapeutics Development 25
AbbVie Inc. 25
Addex Therapeutics Ltd 26
APAvadis Biotechnologies Srl 27
Astellas Pharma Inc. 28
Bayer AG 29
Dongkook Pharmaceutical Co., Ltd. 30
ElexoPharm GmbH 31
EndoCeutics, Inc. 32
Euroscreen S.A. 33
Evotec AG 34
Forendo Pharma Oy 35
GlaxoSmithKline plc 36
Isifer AB 37
Kissei Pharmaceutical Co., Ltd. 38
Lipicard Technologies Limited 39
Neurocrine Biosciences, Inc. 40
Orphagen Pharmaceuticals, Inc. 41
Philogen S.p.A. 42
PregLem SA 43
Repros Therapeutics Inc. 44
SK Chemicals Co., Ltd. 45
Takeda Pharmaceutical Company Limited 46
ValiRx Plc 47
Endometriosis - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
(anastrozole + levonorgestrel) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
acolbifene hydrochloride + GnRH agonist + prasterone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ADX-68692 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ASP-1707 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BAY-1026153 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BAY-1128688 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
bentamapimod - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Drug to Inhibit C-Jun for Endometriosis - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Drug to Target RERG for Endometriosis - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Drugs for Endometriosis - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Drugs for Endometriosis and Uterine Fibroids - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
elagolix sodium - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Endole - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
epelsiban besylate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ESN-364 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
EVE-104 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
F8IL-4 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
FP-5677 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
goserelin biosimilar - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
KLH-2109 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
LT-6121 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
NCE-403 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Peptides for Cancer and Endometriosis - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
PGL-2001 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
relugolix - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
SR-16234 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
telapristone acetate - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
triptorelin pamoate biosimilar - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
VAL-201 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
vilaprisan - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
VPE-001 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Endometriosis - Recent Pipeline Updates 105
Endometriosis - Dormant Projects 118
Endometriosis - Discontinued Products 120
Endometriosis - Product Development Milestones 121
Featured News & Press Releases 121
Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 121
Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 121
Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 121
Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis 122
Apr 25, 2013: ValiRx Receives Australian Patent For VAL201 123
Nov 13, 2012: Repros Presents Proellex Clinical Updates At Lazard Capital Markets 9th Annual Healthcare Conference 123
Oct 08, 2012: Repros Therapeutics's Proellex Receives FDA Acceptance For Reclassification Of Clinical Hold Status 123
Aug 27, 2012: FDA Provides Recommendations For Phase II Protocol For Repros' Proellex In Treatment Of Endometriosis 124
Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 125
Jul 16, 2012: FDA Provides Guidance To Repros For Conducting Phase II Study Of Proellex In Treatment Of Endometriosis 125
Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 127
Disclaimer 127

List of Tables

Number of Products under Development for Endometriosis, H1 2015 12
Number of Products under Development for Endometriosis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2015 17
Comparative Analysis by Late Stage Development, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Development, H1 2015 20
Comparative Analysis by Unknown Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2015 24
Endometriosis - Pipeline by AbbVie Inc., H1 2015 25
Endometriosis - Pipeline by Addex Therapeutics Ltd, H1 2015 26
Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H1 2015 27
Endometriosis - Pipeline by Astellas Pharma Inc., H1 2015 28
Endometriosis - Pipeline by Bayer AG, H1 2015 29
Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 30
Endometriosis - Pipeline by ElexoPharm GmbH, H1 2015 31
Endometriosis - Pipeline by EndoCeutics, Inc., H1 2015 32
Endometriosis - Pipeline by Euroscreen S.A., H1 2015 33
Endometriosis - Pipeline by Evotec AG, H1 2015 34
Endometriosis - Pipeline by Forendo Pharma Oy, H1 2015 35
Endometriosis - Pipeline by GlaxoSmithKline plc, H1 2015 36
Endometriosis - Pipeline by Isifer AB, H1 2015 37
Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 38
Endometriosis - Pipeline by Lipicard Technologies Limited, H1 2015 39
Endometriosis - Pipeline by Neurocrine Biosciences, Inc., H1 2015 40
Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 41
Endometriosis - Pipeline by Philogen S.p.A., H1 2015 42
Endometriosis - Pipeline by PregLem SA, H1 2015 43
Endometriosis - Pipeline by Repros Therapeutics Inc., H1 2015 44
Endometriosis - Pipeline by SK Chemicals Co., Ltd., H1 2015 45
Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 46
Endometriosis - Pipeline by ValiRx Plc, H1 2015 47
Assessment by Monotherapy Products, H1 2015 48
Assessment by Combination Products, H1 2015 49
Number of Products by Stage and Target, H1 2015 51
Number of Products by Stage and Mechanism of Action, H1 2015 53
Number of Products by Stage and Route of Administration, H1 2015 55
Number of Products by Stage and Molecule Type, H1 2015 57
Endometriosis Therapeutics - Recent Pipeline Updates, H1 2015 105
Endometriosis - Dormant Projects, H1 2015 118
Endometriosis - Dormant Projects (Contd..1), H1 2015 119
Endometriosis - Discontinued Products, H1 2015 120

List of Figures

Number of Products under Development for Endometriosis, H1 2015 12
Number of Products under Development for Endometriosis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Products, H1 2015 20
Assessment by Monotherapy Products, H1 2015 48
Assessment by Combination Products, H1 2015 49
Number of Products by Top 10 Targets, H1 2015 50
Number of Products by Stage and Top 10 Targets, H1 2015 50
Number of Products by Top 10 Mechanism of Actions, H1 2015 52
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 52
Number of Products by Top 10 Routes of Administration, H1 2015 54
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 55
Number of Products by Top 10 Molecule Types, H1 2015 56
Number of Products by Stage and Top 10 Molecule Types, H1 2015 57